Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers.

Abnormal regulation of progression from G(1) to S phase of the cell cycle by altered activity of cyclin-dependent kinases (CDKs) is a hallmark of cancer. However, inhibition of CDKs, particularly CDK2, has not shown selective activity against most cancer cells because the kinase seems to be redundant in control of cell cycle progression. Here, we show a novel role in the DNA damage response and application of CDK inhibitors in checkpoint-deficient cells. CDK2(-/-) mouse fibroblasts and small interfering RNA--mediated or small-molecule--mediated CDK2 inhibition in MCF7 or U2OS cells lead to delayed damage signaling through Chk1, p53, and Rad51. This coincided with reduced DNA repair using the single-cell comet assay and defects observed in both homologous recombination and nonhomologous end-joining in cell-based assays. Furthermore, tumor cells lacking cancer predisposition genes BRCA1 or ATM are 2- to 4-fold more sensitive to CDK inhibitors. These data suggest that inhibitors of CDK2 can be applied to selectively enhance responses of cancer cells to DNA-damaging agents, such as cytotoxic chemotherapy and radiotherapy. Moreover, inhibitors of CDKs may be useful therapeutics in cancers with defects in DNA repair, such as mutations in the familial breast cancer gene BRCA1.

[1]  D. Walpita,et al.  Localization of two mammalian cyclin dependent kinases during mammalian meiosis. , 2001, Journal of cell science.

[2]  P. Kaldis,et al.  Cdc2–cyclin E complexes regulate the G1/S phase transition , 2005, Nature Cell Biology.

[3]  Nikolai Zhelev,et al.  In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) , 2002, International journal of cancer.

[4]  M. Trivett,et al.  Brca1 inactivation induces p27Kip1-dependent cell cycle arrest and delayed development in the mouse mammary gland , 2004, Oncogene.

[5]  T. Hunt,et al.  Cyclins and their partners: from a simple idea to complicated reality. , 1991, Seminars in cell biology.

[6]  Phang-lang Chen,et al.  Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. , 2002, Cancer research.

[7]  Mamoru Fukuda,et al.  Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. , 2005, Cancer research.

[8]  Conrad A. Nieduszynski,et al.  The Cyclin A1-CDK2 Complex Regulates DNA Double-Strand Break Repair , 2004, Molecular and Cellular Biology.

[9]  Frank McCormick,et al.  Proliferation of cancer cells despite CDK2 inhibition. , 2003, Cancer cell.

[10]  Lin Tang,et al.  Roscovitine Targets, Protein Kinases and Pyridoxal Kinase*[boxs] , 2005, Journal of Biological Chemistry.

[11]  J. Bourhis,et al.  Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. , 2003, Cancer research.

[12]  E. Lees,et al.  Intra-S-Phase Checkpoint Activation by Direct CDK2 Inhibition , 2004, Molecular and Cellular Biology.

[13]  G. McArthur,et al.  Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis , 2002, Leukemia.

[14]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[15]  W. Forrester,et al.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Senderowicz.  Small-molecule cyclin-dependent kinase modulators , 2003, Oncogene.

[17]  Yosef Shiloh,et al.  Recombinant ATM protein complements the cellular A-T phenotype , 1997, Oncogene.

[18]  E. Hendrickson,et al.  Cell-cycle regulation of mammalian DNA double-strand-break repair. , 1997, American journal of human genetics.

[19]  Jiri Bartek,et al.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair , 2005, Nature Cell Biology.

[20]  P. Ji,et al.  Identification of Interaction Partners and Substrates of the Cyclin A1-CDK2 Complex* , 2004, Journal of Biological Chemistry.

[21]  Pierre Dubus,et al.  Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice , 2003, Nature Genetics.

[22]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[23]  N. Ellis,et al.  Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells. , 2001, Genes & development.

[24]  T. Jacks,et al.  p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells , 1998, The Journal of cell biology.

[25]  G. Enders,et al.  Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. , 2005, Cancer research.

[26]  P. Olive,et al.  The role of DNA single- and double-strand breaks in cell killing by ionizing radiation. , 1998, Radiation research.

[27]  C. Prives,et al.  Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases , 1995, Nature.

[28]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.

[29]  S. West,et al.  CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair , 2005, Nature.

[30]  J. Heierhorst,et al.  ASCIZ regulates lesion‐specific Rad51 focus formation and apoptosis after methylating DNA damage , 2005, The EMBO journal.

[31]  Paul Workman,et al.  The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway , 2004, Cancer Research.

[32]  V. Yamazaki,et al.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.

[33]  Anna Vulpetti,et al.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization. , 2005, Journal of medicinal chemistry.

[34]  T. Hara,et al.  p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thryroid cells , 1997, Oncogene.

[35]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[36]  C. Deng,et al.  Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice , 2003, Development.

[37]  Heinz Ruffner,et al.  BRCA1 Is Phosphorylated at Serine 1497 In Vivo at a Cyclin-Dependent Kinase 2 Phosphorylation Site , 1999, Molecular and Cellular Biology.

[38]  Janice P. Evans,et al.  BRCA2 deficiency in mice leads to meiotic impairment and infertility , 2004, Development.

[39]  M. Kupiec,et al.  The CDK regulates repair of double‐strand breaks by homologous recombination during the cell cycle , 2004, The EMBO journal.

[40]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[41]  Kum Kum Khanna,et al.  BRCA1-BARD1 Complexes Are Required for p53Ser-15 Phosphorylation and a G1/S Arrest following Ionizing Radiation-induced DNA Damage* , 2004, Journal of Biological Chemistry.

[42]  Anna Vulpetti,et al.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. , 2004, Journal of medicinal chemistry.

[43]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.